Ascendis Pharma A (ASND) Net Margin (2014 - 2026)

Ascendis Pharma A has disclosed Net Margin across 13 years of filings, most recently posting 256.45% for Q1 2026.

• Net Margin for Q1 2026 came in at 256.45%, up 16264.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 61.32% (up 5094.0% YoY), and the FY2025 annual result was 32.16%, up 6102.0% from the prior year.
• Net Margin came in at 256.45% for Q1 2026 at Ascendis Pharma A, up from 10.42% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 1837.99% in Q1 2022 to a low of 1332.4% in Q2 2022.
• The 5-year median for Net Margin is 10.42% (2025), against an average of 43.78%.
• Across the five-year window, Net Margin soared 1181574 bps in 2022 and sank 150544 bps in 2023, its largest moves.
• Ascendis Pharma A's Net Margin stood at 905.96% in 2022, then surged by 96 bps to 36.37% in 2023, then surged by 58 bps to 15.24% in 2024, then soared by 32 bps to 10.42% in 2025, then jumped by 2561 bps to 256.45% in 2026.
• The last three Net Margin figures came in at 256.45% (Q1 2026), 10.42% (Q4 2025), and 29.29% (Q3 2025), per Business Quant data.